Close Menu

financial guidance

The $500 million sale of its Illumination and Detection Solutions business will free up capital that can be reinvested in the firm's Human Health and Environmental Health businesses.

23andMe has sent a letter to the heads of the FDA and NIH asking for help in developing broadly applicable standards and guidelines for providing genetic test results and risk estimates.

Already a pioneer in incorporating pharmacogenetic testing into its PBM programs, Medco's decision to buy DNA Direct signals its intent to be a "one-stop shop" for payors and employers interested in using genetically guided medicine to make healthcare more efficient and lower costs.

Caliper Life Sciences' expected Q4 2009 revenues of $37.6 million exceeds the company's previous guidance of $33 to $35 million.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.